| Dubois, Janet |
VAPAUS, NCT05180708: A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita |
|
|
| Recruiting | 3 | 80 | Europe, US | QTORIN 3.9% rapamycin anhydrous gel, Vehicle | Palvella Therapeutics, Inc. | Pachyonychia Congenita | 06/23 | 06/23 | | |
| Active, not recruiting | 3 | 486 | US | saypha® VOLUME Lidocaine, Juvéderm® Voluma™ XC | Croma-Pharma GmbH | Moderate to Severe Midface Volume Deficit | 03/24 | 12/24 | | |
SCALP1, NCT05910450: A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss |
|
|
| Recruiting | 3 | 726 | US, RoW | Clascoterone 5% solution, CB-03-01 5% solution, Vehicle solution, Vehicle | Cassiopea SpA, Ergomed PLC, Pharmapace Inc, Canfield Scientific Inc., ICON Clinical Research | Alopecia, Androgenetic | 06/24 | 01/25 | | |
NCT05662202: Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp |
|
|
| Recruiting | 3 | 165 | US | BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp | Biofrontera Bioscience GmbH | Actinic Keratoses | 09/25 | 03/26 | | |
NCT05802173: Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia |
|
|
| Completed | 2 | 71 | US | TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution | Technoderma Medicines Inc., Therapeutics, Inc. | Alopecia, Androgenetic | 11/23 | 01/24 | | |
NCT05080764: Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults |
|
|
| Recruiting | 2 | 126 | US | 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient) | Biofrontera Bioscience GmbH | Acne Vulgaris | 02/25 | 02/25 | | |
NCT05501327: Dose Regimen Study of SLI-F06 in Healthy Volunteers |
|
|
| Recruiting | 2 | 30 | US | SLI-F06 | Scarless Laboratories, Inc. | Scar, Wound Healing | 07/24 | 10/24 | | |
| Not yet recruiting | 1 | 9 | US | ENS-002 | Concerto Biosciences | Atopic Dermatitis, Atopic Dermatitis Eczema | 12/24 | 12/24 | | |
NCT06074315: Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis |
|
|
| Recruiting | N/A | 338 | US | Nail Genesis DLSO Product, Nail Genesis DLSO Product (vehicle only) | Nail Genesis LLC | Distal Lateral Subungual Onychomycosis, Onychomycosis | 01/25 | 01/25 | | |
